These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35067961)

  • 41. Advances in targeted therapy for anaplastic thyroid carcinoma.
    Qian C; Jiang L; Xu S; Wang J; Tan Z; Xin Y; Ge M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):685-693. PubMed ID: 35347921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating BRAF
    Lubitz CC; Zhan T; Gunda V; Amin S; Gigliotti BJ; Fingeret AL; Holm TM; Wachtel H; Sadow PM; Wirth LJ; Sullivan RJ; Panka DJ; Parangi S
    Thyroid; 2018 Mar; 28(3):328-339. PubMed ID: 29378474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.
    Bueno F; Smulever A; Califano I; Guerra J; Del Grecco A; Carrera JM; Giglio R; Rizzo M; Lingua A; Voogd A; Negueruela MDC; Abelleira E; Pitoia F
    Endocrine; 2023 Apr; 80(1):134-141. PubMed ID: 36617605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
    Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
    J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
    Sandulache VC; Williams MD; Lai SY; Lu C; William WN; Busaidy NL; Cote GJ; Singh RR; Luthra R; Cabanillas ME
    Thyroid; 2017 Jan; 27(1):81-87. PubMed ID: 27785980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
    Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
    Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.
    Agarwal R; Wang J; Wilson K; Barrett W; Morris JC
    J Natl Compr Canc Netw; 2016 Oct; 14(10):1203-1207. PubMed ID: 27697975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 50. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
    Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
    Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
    Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
    Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
    Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
    Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience.
    Park J; Jung HA; Shim JH; Park WY; Kim TH; Lee SH; Kim SW; Ahn MJ; Park K; Chung JH
    Eur J Endocrinol; 2021 May; 184(6):837-845. PubMed ID: 33852431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
    Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complete response of metastatic
    Lee SJ; Song SY; Kim MK; Na HG; Bae CH; Kim YD; Choi YS
    World J Clin Cases; 2023 Sep; 11(27):6664-6669. PubMed ID: 37900238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N; Nucera C
    J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.
    Jungels C; Pita JM; Costante G
    Curr Opin Oncol; 2023 Jan; 35(1):1-9. PubMed ID: 36398690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review.
    Song Y; Bai Y; Wang J; Xu G; Wang T; Zhang B
    Endocr J; 2023 Feb; 70(2):223-228. PubMed ID: 36351596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.